Steady erosion not dramatic plunge likely as Actos faces first generics in Japan
This article was originally published in Scrip
This month's delayed reimbursement price listing of generic products in Japan will include the first such competition to Takeda's big selling oral antidiabetic Actos (pioglitazone), with Sawai and Towa Yakuhin among the leading local firms in the sector set to enter the fray.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.